Tests conducted by an independent laboratory for Chicago-based Avery Dennison Medical Solutions, a division of Avery Dennison Corporation, show that the new Avery Dennison Medical Solutions Chlorhexidine Gluconate (CHG) adhesive delivery system (ADS) may be appropriate for applications where the spread of infection is a concern and moisture management and transparency are required, such as for the securing of IV catheters, surgical incision films, and post-op dressings.

The new CHG ADS is transparent and allows an access or incision site to be seen, a critical parameter for vascular access and post-op dressings. The formulation will ultimately lend itself to use as a transparent film dressing that will make it easier to monitor sites such as catheter insertions.

In cytotoxicity tests, the CHG ADS formulation outperformed two commercial products containing CHG by exhibiting a grade 0 cytotoxicity profile. A poster on the CHG ADS findings is available at http://www.medical.averydennison.com/downloads/resources/ADMS_CHG%20ADS_Poster_final.pdf